Should I buy Medtronic stock in 2025? NZ Edition

What is Medtronic?

How much is the Medtronic stock?

The price of Medtronic stock is rising this week. Currently, Medtronic (MDT) trades at $82.41 USD, up 1.44% over the past 24 hours, though showing a slight weekly decline of 1.85%.

The company holds a market capitalization of $104.19 billion, with an average 3-month trading volume at 7.74 million shares.

With its relatively stable performance and robust dividend, MDT may appeal to NZ investors looking for balanced growth and defensive characteristics in their global portfolio.

Our full analysis on Medtronic stock

After a thorough assessment of Medtronic’s latest financial results and an in-depth review of its share performance over the past three years, our proprietary models have integrated a spectrum of data—from financial ratios and technical patterns to sector momentum and competitor activity. Medtronic (NYSE: MDT) emerges at a potential inflection point, with new strategic initiatives and robust fundamentals poised to shape its future. So, why might Medtronic stock once again become a strategic entry point into the global healthcare technology sector in 2025?

Recent performance and market context

Medtronic’s stock, trading currently at $82.41 USD (as of 30 May 2025), has demonstrated resilience amid broad market volatility. Over the past twelve months, MDT shares have achieved a modest gain of +2.25%, outperforming many global medtech peers in an environment characterized by rising rates and shifting healthcare dynamics. While the stock has experienced a mild dip of -4.77% over the past six months, recent weeks have pointed to stabilisation and emerging upside momentum.

Notably, Medtronic recently announced a bold strategic move: the planned spin-off of its Diabetes segment (representing 8% of revenues, or $2.8 billion annually) into a stand-alone publicly traded entity within 18 months. This initiative is designed to unlock latent value and sharpen Medtronic’s focus on higher-growth divisions—an approach widely applauded by analysts.

The broader macroeconomic backdrop remains supportive. Healthcare spending is structurally robust both in the US and globally, and the medtech sector is benefiting from an acceleration in elective procedures post-pandemic, a trend highly relevant to Medtronic’s Cardiovascular and Surgical portfolios. In New Zealand and the wider APAC region, increasing investments in health infrastructure further enhance demand for advanced medical technologies, making Medtronic particularly well-positioned for regional growth. These elements combine to create a market context that seems to justify renewed optimism around MDT shares.

Technical analysis

From a technical perspective, Medtronic presents a nuanced yet encouraging picture for investors searching for an attractive setup. The Relative Strength Index (RSI) sits at 57.71, signifying underlying buying momentum but leaving room for further upside before approaching overbought territory. Importantly, the short-term 20-day moving average ($81.62) provides a bullish buy signal, with the current price just above this level—an auspicious sign for near-term accumulation.

While longer-term moving averages (50, 100, and 200 days) currently display resistance above the share price, the stock is approaching a zone of consolidation where a bullish reversal often materializes, especially around strong technical support. The key support level at $82.95 is holding, and MDT has successfully defended the lower bound of its recent 52-week range ($75.96 - $96.25), highlighting investor conviction.

Momentum indicators suggest any further pullbacks could represent compelling buy-the-dip opportunities. MACD remains slightly negative, hinting at past softness, but the underlying shift in sector sentiment and recent volume surges reinforce a constructive outlook. Given these factors, MDT seems poised to enter a new bullish phase as technical and fundamental tailwinds align.

Fundamental analysis

Medtronic’s recent Q4 FY2025 results underscore the company’s formidable growth and execution capabilities. Revenue for the quarter reached $8.292 billion (+2.5% reported, +4.1% organic), handily beating analyst forecasts. Net income surged to $1.057 billion (+62% YoY), and EPS advanced +67% to $0.82, both well ahead of expectations. For the full fiscal year, annual revenue hit $33.54 billion, with net income leaping +27% and annual EPS rising +31%. Such robust earnings momentum is especially remarkable given a challenging operating backdrop.

Valuation remains a strong pillar of the bull case: MDT currently trades at a forward P/E of 14.6—modestly below the historical sector average and most key global peers, including Stryker and Boston Scientific. The price-to-sales (P/S) and price-to-earnings-growth (PEG) ratios also point to attractive multiples given Medtronic’s projected organic revenue growth of 4.75%-5% for FY2025. A solid dividend yield of 3.45% further underpins total return expectations, a factor valued highly by long-term, income-seeking investors in New Zealand.

Structurally, Medtronic’s leadership across cardiovascular, neuromodulation, surgical, and diabetes devices is unrivaled. Continued investment in next-generation medical technologies—such as the Hugo robotic system, innovative ablation therapies, and expanded solutions for diabetes management—ensures long-term competitiveness and market share expansion. With a diversified product portfolio and a global footprint, Medtronic remains a clear leader at the nexus of healthcare and technology.

Volume and liquidity

Trading volumes in Medtronic remain robust, with recent daily turnover (8.09 million shares) outpacing the 65-day average (7.74 million shares), reflecting sustained institutional and retail interest. This elevated volume reinforces market confidence and helps underpin favorable price dynamics, providing reassurance to NZ and global investors prioritizing liquidity and execution quality.

The large, but not unwieldy, free float ensures MDT is subject to efficient price discovery while remaining agile enough for dynamic re-rating scenarios. This balance is crucial for investors seeking both defensive qualities and exposure to upward valuation swings during periods of sector or company-specific momentum.

Catalysts and positive outlook

Multiple near- and medium-term catalysts are converging to set the stage for further upside. Key drivers include:

• Pulsed Field Ablation (PFA): This segment is growing at 22% and is already on track for $2 billion in annual revenue, reflecting Medtronic’s leadership in transformative cardiac procedures.
• Renal Denervation: New Medicare coverage, expected within the next eight months, could dramatically increase access and adoption for this innovative hypertension therapy.
• Hugo Robotic Surgery System: With US FDA submissions for urology underway and global deployments progressing, Hugo stands to capture a rapidly expanding market for minimally invasive robotic surgeries.
• MiniMed 780G: Continued double-digit growth, alongside expansion into Type 2 diabetes applications, reinforces Medtronic’s ability to capture high-value patient segments.
• Diabetes Spin-Off: The anticipated separation of the Diabetes division is designed to crystallize additional value for shareholders, allowing sharper operational focus and margin expansion across Medtronic’s core franchises.

Favourable regulatory tailwinds, continued innovation, and Medtronic’s proactive ESG strategy—emphasising sustainability, diversity, and access to care—further enhance sentiment. The consensus price target of $95.84 (+16.3% vs. current) from 33 analysts supports the notion that material upside remains within reach.

Investment strategies

From a portfolio construction perspective, Medtronic offers an appealing risk-reward profile across investment horizons:

• Short-term:
• Technical support at $82.95 offers a precise entry anchor, particularly with signs of renewed buying pressure.
• Anticipation of catalysts (e.g., Diabetes business separation or Medicare coverage approval) could drive rapid re-rating moves in coming quarters.
• Medium-term:
• The next 6–12 months bring several value-unlocking events, including product rollouts, clinical data releases, and further clarification of the Diabetes spin-off. This window may prove ideal for investors seeking asymmetric upside amid contained risk.
• Long-term:
• Medtronic’s entrenched leadership, diversified innovation pipeline, and consistent dividend growth (currently yielding 3.45%) make MDT a compelling core holding for those seeking exposure to global healthcare megatrends.
• A forward P/E below peer averages suggests the possibility of multiple expansion as growth accelerates, with ESG and demographic tailwinds underpinning sustained demand throughout the 2020s.

In each scenario, positioning at or near current levels appears timely, especially ahead of value-creating corporate action and sector-wide tailwinds.

Is it the right time to buy Medtronic?

Medtronic combines several key elements that justify serious consideration: a proven track record of earnings outperformance, attractive forward valuation, robust dividend, and a pipeline of forthcoming catalysts—including the transformative Diabetes spin-off and leading-edge medical innovations. The technical backdrop, anchored by sturdy support and improving sentiment, suggests that downside may be limited while upside could be unlocked by both organic and strategic levers.

For New Zealand investors searching for resilient global opportunities that blend income, growth, and innovation, Medtronic’s case appears stronger than ever. The fundamentals, paired with dynamic company-specific and sector catalysts, seem to support the view that MDT may be entering a new bullish phase—one that could reward well-timed positioning and patient capital alike.

In a medtech landscape that increasingly rewards innovation and execution, Medtronic clearly stands out as a stock warranting renewed attention and careful inclusion in forward-looking portfolios.

How to buy Medtronic stock in New Zealand?

Buying Medtronic (MDT) shares online is a straightforward and secure process for New Zealand investors, thanks to the range of regulated online brokers available today. Whether you’re looking to invest in Medtronic for the long-term (spot buying) or prefer more dynamic approaches such as trading Contracts for Difference (CFDs), both options are accessible and manageable even for beginners. Each method has its own advantages and risk profiles. Further down, you’ll find a broker comparison tool to help you select the platform best suited to your needs.

Spot buying

A cash purchase means you buy actual Medtronic shares and become a direct shareholder, entitling you to dividends and voting rights. New Zealand brokers usually convert your NZD to USD, and will typically charge a fixed commission per trade—often around NZ$5–$15 per order. For example, if the Medtronic share price is $82.41 USD (around NZ$133), you could buy approximately 7 shares with a NZ$1,000 investment (after accounting for, say, a NZ$5 brokerage fee).

Example: Spot buying scenario

Gain scenario: If the Medtronic share price increases by 10%, your holdings would now be worth about NZ$1,100.
Result: That’s a NZ$100 gross gain, or +10% on your original investment.

Trading via CFD

CFDs (Contracts for Difference) allow you to speculate on Medtronic’s share price movement without owning actual shares. CFD trading enables leverage—meaning you can control a larger position with less capital—making it appealing to more active investors. Fees come in the form of the spread (the small difference between buying and selling prices) and overnight financing costs if you hold positions for multiple days. For instance, with NZ$1,000 and 5× leverage, you can gain exposure to NZ$5,000 worth of Medtronic shares via CFDs.

Example: CFD trading scenario

Gain scenario: If Medtronic’s share price rises by 8%, your position gains 8% × 5 = 40%.
Result: That’s a NZ$400 gain on your NZ$1,000 position (excluding fees).

Final advice

Before you invest, it’s important to carefully compare brokers’ fees (including currency conversion, commissions, and CFD financing) and terms. Your best option depends on your approach: long-term investors may prefer direct share ownership and dividends, while active traders might value the flexibility and leverage of CFDs. Explore the broker comparator further down the page to find the platform that matches your goals.

Our 7 tips for buying Medtronic stock

The latest news about Medtronic

Medtronic reported strong Q4 financial results, with both revenue and earnings exceeding analyst expectations. For the quarter ending in April 2025, Medtronic delivered $8.292 billion in revenue, representing organic growth of 4.1% year-on-year, and a net profit of $1.057 billion—an impressive 62% jump over Q4 2024. Earnings per share also climbed significantly, up 67% to $0.82, contributing to a robust annual net income increase of 27% from the prior year. These positive surprises provided renewed momentum for the stock and reinforce Medtronic’s resilience and execution strength, factors closely watched by New Zealand investors seeking steady exposure to the global medical device sector.

Medtronic announced a major strategic move to spin off its Diabetes division as an independent, publicly traded company within 18 months. This decision, communicated on May 21, 2025, targets unlocking value for shareholders and allowing focused growth in Medtronic’s higher-performing core businesses. The Diabetes business, generating $2.8 billion and about 8% of group sales, has proven relevant for New Zealand, where Medtronic’s MiniMed insulin pump systems are an established technology and the local diabetes device market is growing. The spin-off signals an acceleration in tailored innovation, beneficial for patients and clinicians in both global and Australasian healthcare systems, and is anticipated to yield clearer growth stories for both entities.

Technical and analyst signals remain constructive, with a consensus price target well above current levels and a solid dividend yield. As of May 30, 2025, the consensus 12-month target price is $95.84—about 16% above the current share price—supported by a forward price/earnings ratio of 14.6 and a healthy 3.45% dividend yield. The RSI stands at 57.7, suggesting buying momentum, while the 20-day moving average also signals an entry point for investors. This consensus optimism and relative valuation appeal are noteworthy for New Zealand institutions and individuals who favor blue chip defensive equities with reliable income streams.

Medtronic’s rapid product innovation pipeline, especially in robotics, ablation therapies, and diabetes care, enhances its competitive positioning. Recent updates highlight 22% annual growth in pulsed field ablation sales, ongoing next-generation product submissions (such as the Hugo robotic system to the FDA), and continued rapid global uptake of the MiniMed 780G insulin delivery system, including Type 2 diabetes expansion. These strengths are particularly meaningful for New Zealand, where Medtronic supplies a range of high-tech products to DHBs and private hospitals, supporting ongoing healthcare advancements and positioning the company as a lead innovator for the regional medtech landscape.

New Zealand investors benefit from accessible Medtronic product supply channels, favourable taxation, and robust corporate governance. Medtronic’s established distribution partnerships ensure the continued availability of key cardiac, neurological, and diabetes devices in New Zealand’s market. MDT is fully accessible via main offshore investment platforms (including those used in NZ pension and managed funds), with dividends subject to favourable international tax treaties and credits for NZ holders. With its main listing on the NYSE and a strong global governance structure, the company provides local investors with stability, transparency, and consistent exposure to the world’s largest medical technology group.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.